DRUG METABOLISM REVIEWS

Scope & Guideline

Exploring the intricacies of drug metabolism.

Introduction

Delve into the academic richness of DRUG METABOLISM REVIEWS with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0360-2532
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited States
TypeJournal
Converge1972, from 1974 to 2024
AbbreviationDRUG METAB REV / Drug Metab. Rev.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'Drug Metabolism Reviews' serves as a vital resource for researchers and professionals in pharmacology, toxicology, and drug development, focusing on the complexities of drug metabolism and disposition. Its aims and scopes encompass a wide range of topics within drug metabolism, with an emphasis on both fundamental and applied aspects.
  1. Drug Metabolism Mechanisms:
    Explores the biochemical processes and enzymatic pathways involved in the metabolism of drugs, including phase I and phase II reactions, and the role of cytochrome P450 enzymes.
  2. Pharmacogenetics and Drug Interactions:
    Investigates the genetic factors influencing drug metabolism and the implications of drug-drug and drug-gene interactions on therapeutic outcomes and adverse effects.
  3. Transport Mechanisms in Drug Disposition:
    Focuses on the role of drug transporters in pharmacokinetics, including absorption, distribution, and elimination processes, and their impact on drug efficacy and safety.
  4. Toxicology and Hepatotoxicity:
    Addresses the potential toxic effects of drugs and their metabolites, particularly focusing on hepatotoxicity and the mechanisms underlying drug-induced liver injury.
  5. Biotransformation Research:
    Covers advances in biotransformation studies, including novel methodologies for assessing drug metabolism and the development of predictive models for drug interactions.
  6. Regulatory and Clinical Implications:
    Discusses regulatory guidelines and clinical considerations related to drug metabolism, including in vitro and in vivo methodologies and their translation to clinical practice.
The journal has exhibited a dynamic evolution in its research themes, reflecting the latest advancements in drug metabolism science. This section outlines the trending and emerging scopes that are gaining traction in recent publications.
  1. Pharmacogenomics and Personalized Medicine:
    There is a notable increase in research exploring pharmacogenomics, emphasizing how genetic variations affect drug metabolism and response, thereby supporting the movement towards personalized medicine.
  2. Drug Transporter Studies:
    Emerging interest in the role of drug transporters in drug disposition and interactions is evident, highlighting their significance in pharmacokinetics and the blood-brain barrier.
  3. Innovative Drug Delivery Systems:
    Research on novel drug delivery systems, including nanocarriers and biopolymers, is trending, focusing on improving bioavailability and targeting specific sites, particularly in cancer therapy.
  4. Impact of Gut Microbiota on Drug Metabolism:
    An increasing number of studies are exploring how gut microbiota influences drug metabolism and pharmacokinetics, signifying a growing recognition of the microbiome's role in drug response.
  5. Advanced In Vitro and In Vivo Models:
    The development of sophisticated in vitro and in vivo models for studying drug metabolism and toxicity is on the rise, as researchers seek better predictive tools for clinical outcomes.

Declining or Waning

While 'Drug Metabolism Reviews' continues to be a leading journal in the field, certain themes have shown a decline in focus or frequency of publication. This section highlights these waning scopes, indicating shifts in research priorities or emerging interests.
  1. Natural Product Drug Interactions:
    Research on the pharmacokinetic interactions involving natural products has decreased, possibly due to a growing emphasis on synthetic drug development and biopharmaceuticals.
  2. General Toxicogenomics:
    While still relevant, the broad application of toxicogenomics in drug metabolism studies has seen a reduction in publications, as researchers increasingly focus on specific mechanisms and pathways.
  3. Traditional Pharmacokinetics:
    The traditional approaches to pharmacokinetics are being overshadowed by novel methodologies and advanced technologies, leading to fewer publications centered on classical pharmacokinetic principles.
  4. Basic Mechanisms of Drug Resistance:
    Studies focused solely on the basic mechanisms of drug resistance, without integration into broader clinical or translational contexts, have become less frequent as the field shifts towards targeted therapies and personalized medicine.

Similar Journals

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Delivering High-Impact Research for Healthcare Professionals
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

XENOBIOTICA

Transforming Knowledge on Xenobiotic Effects.
Publisher: TAYLOR & FRANCIS LTDISSN: 0049-8254Frequency: 12 issues/year

XENOBIOTICA is a premier journal in the field of pharmacology and toxicology, published by Taylor & Francis Ltd. With an ISSN of 0049-8254 and E-ISSN 1366-5928, this journal has been at the forefront of research since 1971, providing critical insights and advancements up until 2024. It is recognized for its rigorous peer-reviewed content, occupying a third quartile ranking across various categories including Biochemistry, Health, Toxicology, and Pharmacology as of 2023. The journal serves as a pivotal platform for disseminating innovative findings that address the impact of xenobiotics on health and the environment, making it an essential resource for researchers, professionals, and students engaged in these multidisciplinary fields. While it does not currently offer open access, it is widely respected for its contribution to science, evidenced by its Scopus rankings across different areas of study. The journal encourages submissions that push the boundaries of knowledge and transform our understanding of the effects of chemical substances on living organisms.

Current Drug Safety

Pioneering Insights for Safer Drug Development
Publisher: BENTHAM SCIENCE PUBLISSN: 1574-8863Frequency: 3 issues/year

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

Translational and Clinical Pharmacology

Empowering Pharmacological Insights for Tomorrow
Publisher: KSCPTISSN: 2289-0882Frequency:

Translational and Clinical Pharmacology, published by KSCPT, is an esteemed journal that serves as a vital source of knowledge in the field of pharmacology, particularly focusing on the translational aspects that bridge laboratory research and clinical applications. Established in 2014, this journal aims to disseminate high-quality research and reviews pertaining to drug development, therapeutics, and the underlying mechanisms of action in the medical realm. With an ISSN of 2289-0882 and an E-ISSN of 2383-5427, it holds a significant position with a Q3 ranking in the pharmacology category as of 2023, emphasizing its role in advancing scientific understanding within this crucial discipline. While it operates as a traditional subscription-based journal, its output remains accessible through various academic platforms, contributing to the global discourse in pharmacology. Researchers, professionals, and students will find value in its insightful articles and comprehensive studies, underscoring the journal’s commitment to enhancing pharmacological knowledge and practice.

Asian Journal of Pharmaceutics

Pioneering research in pharmacology and toxicology.
Publisher: ASIAN JOURNAL PHARMACEUTICSISSN: 0973-8398Frequency: 4 issues/year

Asian Journal of Pharmaceutics, with ISSN 0973-8398 and E-ISSN 1998-409X, is a prominent publication in the field of pharmacology, toxicology, and pharmaceutics, published by the ASIAN JOURNAL PHARMACEUTICS. Since its inception in 2009, the journal has been committed to advancing the understanding of pharmaceutical sciences in Asia and beyond, encompassing innovative research, reviews, and perspectives from both established and emerging scholars. Despite its coverage discontinuation in Scopus, it continues to serve as a vital resource for researchers, professionals, and students aiming to explore the dynamic developments in drug formulation, delivery systems, and regulatory affairs. The journal's ranking in the 18th percentile within its category underscores its niche focus and relevance, making it an essential conduit for disseminating knowledge in the pharmaceutical domain. Open access options may enhance its reach and impact, allowing significant findings to be freely accessible to a global audience, thus fostering collaboration and knowledge exchange across borders.

BIOPHARMACEUTICS & DRUG DISPOSITION

Empowering Discoveries in Biopharmaceutics
Publisher: WILEYISSN: 0142-2782Frequency: 6 issues/year

BIOPHARMACEUTICS & DRUG DISPOSITION, published by WILEY, is a prominent journal in the fields of biopharmaceutics and pharmacology, dedicated to the dissemination of vital research that spans from the foundational aspects of drug disposition to advanced therapeutic developments. Since its inception in 1979, this journal has established itself as a crucial resource for a diverse audience, including researchers, professionals, and students. With its impact factor indicating solid performance and a current ranking in Q2 for Pharmaceutical Science and Q3 across miscellaneous medicine categories, BIOPHARMACEUTICS & DRUG DISPOSITION serves as a nexus for innovative studies and breakthrough findings. The journal's comprehensive scope ensures that rigorous scientific inquiry is represented, helping to advance the understanding of drug behavior in biological systems. Participating in this scholarly dialogue not only enhances individual knowledge but contributes to the broader pharmaceutical and medical communities, making it an essential publication for all stakeholders interested in drug development and utilization.

SCIENTIA PHARMACEUTICA

Exploring new horizons in pharmaceutical research.
Publisher: MDPIISSN: Frequency: 4 issues/year

SCIENTIA PHARMACEUTICA, published by MDPI in Switzerland, is a leading open access journal dedicated to advancing the field of pharmaceutical sciences since 2006. With a focus on pharmacology, toxicology, and pharmaceutics, this journal plays a pivotal role in disseminating high-quality research and innovative findings. It boasts an impressive impact factor and is ranked in the second quartile (Q2) for Pharmaceutical Science, signifying its influence within the academic community, aided by a Scopus ranking of 74 out of 183 journals in the same category. SCIENTIA PHARMACEUTICA invites original research articles, reviews, and notes that contribute to the understanding and development of pharmaceutical science, making it an essential resource for researchers, professionals, and students alike seeking to stay at the forefront of this continuously evolving field. For those interested in broadening their knowledge and sharing insights, the journal ensures wide accessibility, supporting the open access model for maximum outreach.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Fostering Collaboration for Transformative Medical Insights
Publisher: WILEYISSN: 0305-1870Frequency: 12 issues/year

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.

THERAPEUTIC DRUG MONITORING

Elevating Standards in Drug Therapy Optimization
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0163-4356Frequency: 6 issues/year

THERAPEUTIC DRUG MONITORING, published by Lippincott Williams & Wilkins, is a prestigious journal that focuses on the critical area of pharmacology, with a specific emphasis on the therapeutic optimization of drug therapy. With an ISSN of 0163-4356 and an E-ISSN of 1536-3694, this peer-reviewed journal has been contributing valuable research and insights to the field since its inception in 1979. As of 2023, it holds a Q2 classification in the Pharmacology category, indicating its prominent role in advancing pharmaceutical sciences. The journal aims to enhance understanding of drug effectiveness and safety through rigorous studies on drug monitoring and individualized therapy, making it an essential resource for researchers, healthcare professionals, and students dedicated to improving patient care. With its solid standing reflected in Scopus rankings, including a rank of #103 in medical pharmacology and a 62nd percentile, THERAPEUTIC DRUG MONITORING continues to be a vital publication for those aiming to contribute to and stay informed about the latest developments in the field.

CHEMICO-BIOLOGICAL INTERACTIONS

Unraveling Complex Interactions for Health Innovations
Publisher: ELSEVIER IRELAND LTDISSN: 0009-2797Frequency: 18 issues/year

CHEMICO-BIOLOGICAL INTERACTIONS is a premier journal published by Elsevier Ireland Ltd, dedicated to advancing the field of chemical and biological interactions since its inception in 1969. With a robust focus on pharmacology and toxicology, the journal holds a prestigious Q1 ranking in both Medicine (miscellaneous) and Toxicology, reflecting its significance in disseminating influential research. As part of the Scopus database, it ranks #21 out of 133 journals in Toxicology, positioning it in the 84th percentile and ensuring high visibility for cutting-edge studies. This scholarly platform serves as a crucial resource for researchers, professionals, and students who seek reliable and innovative findings at the intersection of chemistry and biology. While currently not open access, CHEMICO-BIOLOGICAL INTERACTIONS provides a comprehensive collection of articles that contribute to the ongoing dialogue in toxin research and its implications on medicinal chemistry, thereby fostering advancements in public health and safety.